Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: Final results of the phase III randomized Short-HER study

Vittorio Gebbia, Antonio Russo, Moretti, Giovanardi, Antonella Ferro, Cagossi, Federico Piacentini, Beano, Alba Brandes, Conte, Balduzzi, Vicini, Russo, Rimanti, Ornella Garrone, Saverio Danese, Michele Aieta, Giancarlo Bisagni, Roberto D'Amico, LombardoAlessio Schirone, Roberta Maltoni, Claudio Zamagni, Francesco Giotta, Bisagni, Frassoldati, Michela Donadio, Cavanna, Molino, Paolo Pronzato, Laura Amaducci, Antonino Musolino, Valentina Guarneri

Research output: Contribution to journal › Article › peer-review

95 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: Final results of the phase III randomized Short-HER study'. Together they form a unique fingerprint.

Medicine & Life Sciences